使用SEER和机构队列,开发和验证状胆瘤术后生存预后诺基图
Minglong Li1, Jianli Wang1, Cao Han2
1Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical University, Chengde City, Hebei Province, China.
概括
一个新的预后诺基图准确地预测了手术后状胆瘤 (HCCA) 患者的存活率. 该工具改进了目前的TNM分期,用于个性化风险评估和治疗规划.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 生物统计学 生物统计学
背景情况:
- 美国癌症联合委员会 (AJCC) 第8版TNM分期系统在预测手术切除后状胆瘤 (HCCA) 患者的生存结果方面存在局限性.
- 需要改进的预后工具,为HCCA患者提供个性化的生存估计.
研究的目的:
- 开发和验证用于预测为HCCA.切除的患者的整体存活期 (OS) 的预后性名录.
- 与现有的TNM分期系统对比开发的诺米图的临床实用性.
主要方法:
- 从监测,流行病学和最终结果 (SEER) 数据库 (2000-2021) 和切除的HCCA患者的机构队列 (n=42) 的数据的回顾性分析.
- 采用多变量考克斯回归分析来确定影响生存的独立预后因素.
- 使用包括C指数,接收器操作特征 (ROC) 曲线,校准图表和决策曲线分析 (DCA) 在内的指标构建和验证了一个名ogram.
主要成果:
- 确定的主要独立预后因素包括年龄>70,高瘤级别,晚期T阶段 (T3/T4),N2淋巴结转移,瘤大小>5厘米和辅助化疗的使用.
- 诺米图表表现出良好的预测性能,训练组的C指数为0.708,验证组的C指数为0.696.
- 决策曲线分析表明,与TNM分期系统相比,名图为预测生存率提供了更好的临床实用性.
结论:
- 经过验证的预后名录,结合临床和病理因素,为HCCA患者在切除后的整体生存提供了准确和个性化的预测.
- 这种名图超越了当前TNM分期系统的预测能力,可以帮助风险分层和临床决策.
- 这项研究支持将这种名谱集成到临床实践中,以改善患者管理和治疗计划.
更多相关视频
相关概念视频
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Comparing the Survival Analysis of Two or More Groups
553
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
553


